USA - NYSE:ELAN - US28414H1032 - Common Stock
The current stock price of ELAN is 21.31 USD. In the past month the price decreased by -0.83%. In the past year, price increased by 60.63%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.64 | 991.60B | ||
| JNJ | JOHNSON & JOHNSON | 19.59 | 489.78B | ||
| MRK | MERCK & CO. INC. | 10.78 | 237.31B | ||
| PFE | PFIZER INC | 7.64 | 138.92B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.99 | 93.32B | ||
| ZTS | ZOETIS INC | 18.35 | 51.56B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.28 | 22.25B | ||
| VTRS | VIATRIS INC | 4.39 | 11.93B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.32 | 8.00B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.17B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.08B |
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
ELANCO ANIMAL HEALTH INC
2500 Innovation Way N
Greenfield INDIANA 46140 US
CEO: Jeffrey N. Simmons
Employees: 9000
Phone: 18773526261
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
The current stock price of ELAN is 21.31 USD. The price decreased by -0.7% in the last trading session.
ELAN does not pay a dividend.
ELAN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
21 analysts have analysed ELAN and the average price target is 22.35 USD. This implies a price increase of 4.87% is expected in the next year compared to the current price of 21.31.
ELANCO ANIMAL HEALTH INC (ELAN) currently has 9000 employees.
The outstanding short interest for ELANCO ANIMAL HEALTH INC (ELAN) is 4.49% of its float.
ChartMill assigns a technical rating of 8 / 10 to ELAN. When comparing the yearly performance of all stocks, ELAN is one of the better performing stocks in the market, outperforming 92.51% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ELAN. ELAN has only an average score on both its financial health and profitability.
Over the last trailing twelve months ELAN reported a non-GAAP Earnings per Share(EPS) of 0.96. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.78% | ||
| ROA | 0.27% | ||
| ROE | 0.53% | ||
| Debt/Equity | 0.59 |
21 analysts have analysed ELAN and the average price target is 22.35 USD. This implies a price increase of 4.87% is expected in the next year compared to the current price of 21.31.
For the next year, analysts expect an EPS growth of 1.26% and a revenue growth 4.03% for ELAN